Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope

Virology

Volumn 392, Issue 1, 2009, Pages 82-93

  Zolla Pazner, Susan ^a,b   Cohen, Sandra ^a   Pinter, Abraham ^c   Krachmarov, Chavdar ^c   Wrin, Terri ^d   Wang, Shixia ^e   Lu, Shan ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d MONOGRAM BIOSCIENCES   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

gp120; HIV 1; Immunization; Neutralizing antibodies; Pseudovirus; V3 loop; Vaccine

Indexed keywords

DNA; EPITOPE; GLYCOPROTEIN GP 120; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CLADISTICS; CROSS REACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RABBIT; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; DNA, VIRAL; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RABBITS; RECOMBINANT FUSION PROTEINS;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 69249210887     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.05.039     Document Type: Article

References (70)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 2 (2000) 200-206
2. Baldinotti F., Matteucci D., Maxxetti P., Giannelli C., Bandecchi P., Tozzini F., and Bendinelli M. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J. Virol. 68 7 (1994) 4572-4579
3. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., and Goepfert P.A. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J. Virol. 82 13 (2008) 6458-6469
4. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Haynes J.R., Walker C.M., and Steimer K.S. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15 8 (1997) 869-873
5. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., and Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79 14 (2005) 8812-8827
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
7. Brown B.K., Wieczorek L., Sanders-Buell E., Borges A.R., Robb M.L., Birx D.L., Michael N.L., McCutchan F.E., and Polonis V.R. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375 2 (2008) 529-538
8. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., Sempala S.D., Giraldo G., and Buonaguro F.M. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res. 54 3 (2002) 189-201
9. Buonaguro L., Devito C., Tornesello M.L., Schroder U., Wahren B., Hinkula J., and Buonaguro F.M. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25 32 (2007) 5968-5977
10. Burke B., Gomez-Roman V.R., Lian Y., Sun Y., Kan E., Ulmer J., Srivastava I.K., and Barnett S.W. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 387 2 (2009) 147-156
11. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., and Zolla-Pazner S. Structural Basis of Co-Receptor Selectivity by the HIV-1 V3 Loop. AIDS Res. Hum. Retroviruses 23 3 (2007) 415-426
12. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 2 (1995) 935-944
13. Cox K.S., Clair J.H., Prokop M.T., Sykes K.J., Dubey S.A., Shiver J.W., Robertson M.N., and Casimiro D.R. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J. Virol. 82 16 (2008) 8161-8171
14. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., de Vries R.P., Wiley C., Zharkikh I., Schulke N., Roux K.H., Montefiori D.C., Burton D.R., and Binley J.M. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 2 (2007) 245-262
15. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J.A., Hahn B.H., Kwong P.D., and Shaw G.M. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83 3 (2009) 1240-1259
16. Dimmock N.J. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183 (1993) 1-149
17. Dunkle K.L., Stephenson R., Karita E., Chomba E., Kayitenkore K., Vwalika C., Greenberg L., and Allen S. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 371 9631 (2008) 2183-2191
18. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., and Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191 5 (2005) 666-677
19. Gorny M.K., Revesz K., Williams C., Volsky B., Louder M.K., Anyangwe C.A., Krachmarov C.P., Kayman S.C., Pinter A., Nadas A., Nyambi P.N., Mascola J.R., and Zolla-Pazner S. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. J. Virol. 78 5 (2004) 2394-2404
20. Gorny M.K., Williams C., Volsky B., Revesz K., Wang X.H., Burda S., Kimura T., Koning F.A., Nadas A., Anyangwe C., Nyambi P., Krachmarov C., Pinter A., and Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of HIV-1. J. Virol. 80 14 (2006) 6865-6872
21. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., Keefer M.C., Mulligan M.J., Matthews T.J., Wolinsky S.M., Montefiori D.C., Vermund S.H., Lambert J.S., Corey L., Belshe R.B., Dolin R., Wright P.F., Korber B.T., Wolff M.C., Fast P.E., and Group T.A.V.E. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. J. Infect. Dis. 177 2 (1998) 310-319
22. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Martin J.E., McCluskey M.M., Chakrabarti B.K., Lamoreaux L., Andrews C.A., Gomez P.L., Mascola J.R., and Nabel G.J. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194 12 (2006) 1650-1660
23. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K., Serwadda D., Wabwire-Mangen F., Lutalo T., Li X., vanCott T., and Quinn T.C. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357 9263 (2001) 1149-1153
24. Haigwood N.L., Watson A., Sutton W.F., McClure J., Lewis A., Ranchalis J., Travis B., Voss G., Letvin N.L., Hu S.L., Hirsch V.M., and Johnson P.R. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Letters 51 1-2 (1996) 107-114
25. Hanke T., Goonetilleke N., McMichael A.J., and Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen .Virol. 88 Pt 1 (2007) 1-12
26. Hannoun C., Megas F., and Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103 1-2 (2004) 133-138
27. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S.M., Korber B.T., and Liao H.X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 345 1 (2006) 44-55
28. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69 11 (1995) 6705-6711
29. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., and Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5 5 (2009) e1000433
30. Hill C.M., Deng H.K., Unutmaz D., KewalRamani V.N., Bastiani L., Gorny M.K., Zolla-Pazner S., and Littman D.R. Envelope glycoproteins from HIV-1, HIV-2 and SIV can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 71 (1997) 6296-6304
31. Kayman S.C., Wu Z., Revesz K., Chen H., Kopelman R., and Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 68 1 (1994) 400-410
32. Krachmarov C.P., Kayman S.C., Honnen W.J., Trochev O., and Pinter A. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 18 (2001) 1737-1748
33. Krachmarov C., Pinter A., Honnen W.J., Gorny M.K., Nyambi P.N., Zolla-Pazner S., and Kayman S.C. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 79 2 (2005) 780-790
34. Krachmarov C., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., and Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 80 14 (2006) 7127-7135
35. Law M., Cardoso R.M., Wilson I.A., and Burton D.R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81 8 (2007) 4272-4285
36. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., Montefiori D.C., Sodroski J., and Robinson H.L. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14 2 (1998) 151-155
37. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 2 (2000) 207-210
38. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., Vancott T.C., Huang Y., Chakrabarti B.K., Kong W.P., Yang Z.Y., Xu L., Montefiori D.C., Nabel G.J., and Letvin N.L. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79 2 (2005) 771-779
39. Morner A., Douagi I., Forsell M.N., Sundling C., Dosenovic P., O'Dell S., Dey B., Kwong P.D., Voss G., Thorstensson R., Mascola J.R., Wyatt R.T., and Karlsson Hedestam G.B. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83 2 (2009) 540-551
40. Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C., Ferrari G., Weinhold K.J., Smith J.M., Amara R.R., and Robinson H.L. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses 22 7 (2006) 678-683
41. Nyambi P.N., Nadas A., Mbah H.A., Burda S., Williams C., Gorny M.K., and Zolla-Pazner S. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J. Virol. 74 22 (2000) 10670-10680
42. Pantophlet R., Aguilar-Sino R.O., Wrin T., Cavacini L.A., and Burton D.R. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364 2 (2007) 441-453
43. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001) 195-262
44. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 17 (2001) 8340-8347
45. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47 3 (2008) 401-409
46. Polonis V.R., Brown B.K., Borges A.R., Zolla-Pazner S., Dimitrov D.S., Zhang M.Y., Barnett S.W., Ruprecht R.M., Scarlatti G., Fenyo E.M., Montefiori D.C., McCutchan F.E., and Michael N.L. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375 2 (2008) 315-320
47. Richards F.F., Konigsberg W.H., Rosenstein R.W., and Varga J.M. On the specificity of antibodies. Science 187 4172 (1975) 130-137
48. Richman D.D., Wrin T.L., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Nat'l Acad. Sci. USA 100 7 (2003) 4144-4149
49. Richmond J.F., Lu S., Santoro J.C., Weng J., Hu S.L., Montefiori D.C., and Robinson H.L. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol. 72 11 (1998) 9092-9100
50. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., and Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280 5371 (1998) 1949-1953
51. Robbins J.B., Schneerson R., and Szu S.C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171 6 (1995) 1387-1398
52. Rosen O., Samson A.O., Sharon M., Zolla-Pazner S., and Anglister J. Response to Matters Arising: HIV-1 Coreceptor Selectivity. Structure 14 (2006) 649-651
53. Schweighardt B., Liu Y., Huang W., Chappey C., Lie Y.S., Petropoulos C.J., and Wrin T. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J. Acquir. Immune. Defic. Syndr. 46 1 (2007) 1-11
54. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., Koup R.A., Mascola J.R., Nabel G.J., and Letvin N.L. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79 5 (2005) 2956-2963
55. Sharon M., Kessler N., Levy R., Zolla-Pazner S., Gorlach M., and Anglister J. Alternative conformations of HIV-1 V3 loops mimic B hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb) 11 2 (2003) 225-236
56. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., and Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 2 (1999) 204-210
57. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., and Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human antibody 447-52D. Structure 12 2 (2004) 193-204
58. Stanfield R.L., Gorny M.K., Zolla-Pazner S., and Wilson I.A. Crystal structures of HIV-1 neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80 12 (2006) 6093-6105
59. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., and Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 6605 (1996) 184-187
60. Vaine M., Wang S., Crooks E.T., Jiang P., Montefiori D.C., Binley J., and Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J. Virol. 82 15 (2008) 7369-7378
61. von Bubnoff, A. (2008). The great barrier: Understanding mucosal immune responses is critical to developing effective AIDs vaccines, but progress has been slow. IAV Report, March-April, 10-14.
62. Wang W.K., Dudek T., Essex M., and Lee T.H. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc. Nat'l. Acad. Sci. USA 96 8 (1999) 4558-4562
63. Wang S., Arthos J., Lawrence J.M., Van Ryk D., Mboudjeka I., Shen S., Chou T.H., Montefiori D.C., and Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J. Virol. 79 12 (2005) 7933-7937
64. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., Liu Q., Whitney S., Keen T., Nair B.C., Kalyanaraman V.S., Markham P., and Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 1 (2006) 34-47
65. Wicker S., Rabenau H.F., Gottschalk R., Doerr H.W., and Allwinn R. Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med. Microbiol. Immunol. 196 3 (2007) 145-150
66. Wu L., Yang Z.Y., Xu L., Welcher B., Winfrey S., Shao Y., Mascola J.R., and Nabel G.J. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 24 23 (2006) 4995-5002
67. Yamamoto H., Kawada M., Takeda A., Igarashi H., and Matano T. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2 6 (2007) e540
68. Zolla-Pazner S. Mechanisms contributing to the neutralization of HIV-1. Immunol. letters 51 (1996) 89-93
69. Zolla-Pazner S., Zhong P., Revesz K., Volsky B., Williams C., Nyambi P., and Gorny M.K. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res. Hum. Rertroviruses 20 11 (2004) 1254-1258
70. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., and Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372 2 (2008) 233-246